51Cr-Bleomycin, a New Oncophilic Radiopharmaceutical II. Scintigraphic Diagnosis of Malignant Neoplasms

1982 ◽  
Vol 21 (02) ◽  
pp. 68-71 ◽  
Author(s):  
D. Brykalski ◽  
T. Pertyński ◽  
Maria Rembelska ◽  
K. Durski ◽  
S. Fajndt ◽  
...  
Keyword(s):  
Gamma Camera ◽  
Malignant Neoplasms ◽  
Cervix Carcinoma ◽  
Malignant Lymphomas ◽  
Hodgkins Lymphoma ◽  
67Ga Citrate

51Cr-bleomycin was used for the scintigraphic detection of tumours and the assessment of the spread of the disease in 20 patients with various malignances: 7 with Hodgkins Lymphoma, 5 with other malignant lymphomas, 4 cases of cervix carcinoma and 4 other tumours. The scintigraphy was performed using a Toshiba GC 401 gamma camera coupled to an MDSI computer Trinary. Active foci were scored using a semiquantitative scale of 0 to 5. Results of these studies were compared with those of tests similarly carried out with 57Co-bleomycin (in 9 of the cases) and 67Ga-citrate (11 cases); they demonstrated that the properties of 51Cr-bleomycin for scintigraphic detection of neoplastic foci are similar to those of 57Co-bleomycin.

PREDICTIVE SIGNIFICANCE OF HIGH SERUM FERRITIN LEVELS IN THE DEBUT OF MALIGNANT LYMPHOMA

2020 ◽  
pp. 74-81
Author(s):  
Babaeva T.N. ◽  
Seregina O.B. ◽  
Pospelova T.I.
Keyword(s):  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Prognostic Significance ◽  
Average Concentration ◽  
High Serum ◽  
Control Group ◽  
Malignant Neoplasms ◽  
Significant Prognostic Factor ◽  
Malignant Lymphomas

At present, the serum ferritin level is not included in the list of prognostic factors; however, it is known that its increased serum level in patients with malignant neoplasms relates with the tumor burden, the degree of disease activity and correlates with a worse prognosis in patients with hematologic malignancies.The normalization of serum ferritin level during remission period confirms the involving of hyperferritinemia in mechanisms of tumor progression and may testify for clinical importance of measurement of serum ferritin level in patients, including those with malignant lymphomas. Objective:The aim of this study was to assess of the prognostic significance of high ferritin levels at the onset of the disease in patients with malignant lymphomas. Materials and methods:98 patients with malignant lymphomaswere enrolled in this study, including 72 patients (73.5%) with non-Hodgkins lymphomas (NHL) and 26 patients (26.5%) with Hodgkin’s lymphoma (HL). The increased serum ferritin level (more than 350 ng/ml) was found in 53 (54.2%) patients with malignant lymphomas at the onset of disease and its average concentration was 587,62±131,6 ng/ml (8.3 times higher values of control group, p<0.001).Also the positive statistical correlationsbetween increased ferritin level and increased level of LDH (r=0.47, p<0.001, n=98) and C-reactive protein (r=0.41, p<0.001, n=98) as well as the presence of B-symptomswere found. The median OS was significantly shorter in the group of patients with increased ferritin level (more than 350 ng/ml) at the onset of disease in comparison with group of patients with normal ferritin level, where the median OS was not reach during the observation period. Patients with increased ferritin level before starting chemotherapy also showed worse results of overall survival and increased mortality risk (OR 8.122; 95% CI, 1.764-37.396;р<0.05) compare with a group of patients with ferritin level ˂350 hg/ml at the onset of disease. Conclusion:These results make it possible to include lymphomas’s patients with increased ferritin level at the onset of disease in the group with poor prognosis and lower OS, while the increased ferritin level in patients without previous blood transfusions should be considered as a significant prognostic factor.

scholarly journals Autoimmune Disease in NZB/Bl Mice

Blood ◽  
1966 ◽  
Vol 27 (4) ◽  
pp. 435-448 ◽  
Author(s):  
ROBERT C. MELLORS ◽  
Dolores A. Landy ◽  
David Bardell
Keyword(s):  
Autoimmune Disease ◽  
Malignant Lymphoma ◽  
Plasma Cells ◽  
Membranous Glomerulonephritis ◽  
Lymphoid Cells ◽  
Malignant Neoplasms ◽  
Reticulum Cell ◽  
Malignant Lymphomas ◽  
Lymphoid Neoplasia ◽  
Histologic Types

Abstract Malignant lymphoma was found in 4 of 20 NZB/Bl mice (of the 61st generation) selected for laboratory examinations and autopsy at 9 to 11 months of age. The malignant lymphomas were of two histologic types, reticulum cell sarcoma and pleomorphic malignant lymphoma, the latter term being used to designate malignant neoplasms arising in lymphatic tissue, composed of mesenchymal cells of diverse appearance—mainly plasma cells of blast, immature, mature and Russell-body types but also large primitive (stem) cells, reticulum cells, and lymphocytes of large and small size—and frequently associated with gammopathies. One of the reticulum cell sarcomas was transplantable to, and produced lethal disseminated growth in, other NZB/Bl mice. In each example of malignant lymphoma, warm hemagglutinins (to papain-treated mouse red cells) were demonstrable in serum. Autoimmune hemolytic disease and chronic membranous glomerulonephritis, both of common occurrence in NZB/Bl mice of comparable age, were also present. In one instance of pleomorphic malignant lymphoma, hypergammaglobulinemia of unusual quantity and quality drew attention to the possibility of lymphomatous disease. Some evidence was brought forth indicating that in the majority of instances the autoimmune diseases preceded the malignant lymphomas. While the coexistence of autoimmunity and lymphoid neoplasia conceivably reflects nothing more than chance occurrence, other interpretations were considered: the proliferative advantage engendered in immunologically competent cells in autoimmune disease may be a step in the direction of lymphoid neoplasia; or, in some instances autoantibodies may be produced by, or in response to, the neoplastic lymphoid cells.

Clinical manifestation of malignant lymphomas of the head and neck region

2017 ◽  
Vol 71 (6) ◽  
pp. 14-21 ◽  
Author(s):  
Katarzyna Bojanowska-Poźniak ◽  
Wioletta Pietruszewska
Keyword(s):  
Head And Neck ◽  
Hodgkin Lymphoma ◽  
Young Patients ◽  
Neck Region ◽  
Lymphoid Cells ◽  
Diagnostic Process ◽  
Malignant Neoplasms ◽  
Malignant Lymphomas ◽  
Head And Neck Region ◽  
Medical University

Introduction: Malignant lymphoma (ML) is a neoplasm caused by clonal expansion of undifferentiated B, T and NK-lymphoid cells. WHO classification divides lymphomas into two main types, i.e. Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL), with numerous subtypes. The majority of MLs are localized in lymph nodes, but extranodal locations are also possible. MLs represent approximately 3-5% of all malignant neoplasms in Poland, but their incidence has been increasing in recent years, especially in young patients. The objective of the study was to evaluate clinical manifestations and diagnostic process in patients with malignant lymphomas of the head and neck region as diagnosed in the Department of Otorhinolaryngology of the Medical University of Lodz in years 2013-2017. Material and method: 30 patients diagnosed with malignant lymphomas of the head and neck region at the Departbadament of Otorhinolaryngology of the Medical University of Lodz in 2013-2017. Results: The study group consisted of 8 cases of nodal lymphomas and 22 cases of extranodal lymphomas. In 29 cases B-cell lymphomas were diagnosed. The most common symptoms included lymphadenopathy or neck tumor. Other symptoms were associated with the location of tumors in particular body organs. The diagnosis was based on histopathological examination of biopsy (needle or surgical) samples. Conclusion: Malignant lymphomas should be taken into account during differential diagnosis of the tumor or lymphadenopathy of the neck. The diagnosis is difficult because of the nonspecificity of symptoms and the need for interdisciplinary cooperation of many specialists.

Primary Malignant Neoplasms of the Duodenum. Excluding the Papilla of Vater

1956 ◽  
Vol 30 (3) ◽  
pp. 421-431 ◽  
Author(s):  
Arthur Burgerman ◽  
Archie H. Baggenstoss ◽  
James C. Cain
Keyword(s):  
Malignant Neoplasms ◽  
Papilla Of Vater

Quantitative measurement of cerebral metabolic rate of glucose by means of dual-head coincidence gamma camera and 2-deoxy-2- [18F] fluoro-D-glucose

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S670-S670
Author(s):  
Katsufumi Kajimoto ◽  
Naohiko Oku ◽  
Yasuyuki Kimura ◽  
Makiko Tanaka ◽  
Hiroki Kato ◽  
...  
Keyword(s):  
Metabolic Rate ◽  
Gamma Camera ◽  
Quantitative Measurement ◽  
Cerebral Metabolic Rate

Comparative Chemical, Biological and Clinical Studies of 99mTc-Glucoheptonate and 99mTc-Dimercaptosucci- nate as Used in Renal Scintigraphy

1979 ◽  
Vol 18 (01) ◽  
pp. 40-45 ◽  
Author(s):  
M. Malešević ◽  
Lj. Stefanović ◽  
N. Vanlić-Razumenić
Keyword(s):  
Clinical Studies ◽  
Gamma Camera ◽  
Radiochemical Purity ◽  
Renal Cortex ◽  
Renal Scintigraphy ◽  
Time Intervals ◽  
Experimental Animals ◽  
Dynamic Studies

The renal radiopharmaceutical preparations 99mTc-DMS and 99mTc-GH were examined chemically, biologically and clinically. Both preparations are of high radiochemical purity. The biodistribution of both preparations was examined in experimental animals at different time intervals, from 15 min to 4 hr; the percentage of incorporation of 99mTc-DMS into kidneys is much higher (29.4% to 52.0%) than that of 99mTc-GH (12.80% to 22.20%). Both preparations accumulate to a greater extent in the renal cortex than in the medulla.The most suitable time for renal scintigraphy for "mTc-DMS is 90-150 min while for 99mTc-GH it is 60-90 min. It is concluded that 99mTc-DMS is more suitable for static scintigrams on the scanner and 99mTc-GH for dynamic studies with the gamma camera.

Quantitative Radioisotope Measurement of Duodenogastric Reflux in Patients with Ulcer or Gastrectomized for Ulcer

1985 ◽  
Vol 24 (03) ◽  
pp. 107-110
Author(s):  
M. Pääkkönen ◽  
S. Aukee ◽  
K. Korhonen ◽  
A. Pääkkönen ◽  
E. Länsimies ◽  
...  
Keyword(s):  
Gamma Camera ◽  
Background Activity ◽  
Bile Reflux ◽  
Duodenogastric Reflux ◽  
Upper Limit ◽  
Visual Evidence ◽  
Biochemical Measurement

SummaryIn this work the duodenogastric reflux was quantified as the amount of radioactivity entering the stomach after an i.v. administration of 99mmTc-HIDA in ulcer patients and in patients who had undergone BI gastrectomy. The results were compared with visual evidence of gastric activity in the gamma camera images and biochemical determination of gastric bile reflux. The method is useful in quantifying the reflux if the activity is above the background activity. It allows the determination of an upper limit for the reflux when the reflux is evident visually. Only two or three images are needed for the quantitation. No correlation was found between biochemical measurement of fasting bile reflux in the stomach and radioisotopic quantification.

On the Determination of the Resolution Index of a Gamma Camera

1973 ◽  
Vol 12 (04) ◽  
pp. 360-366
Author(s):  
Barbara Gwiazdowska ◽  
H. Mackiewicz ◽  
J. Tolwinski
Keyword(s):  
Gamma Camera

L’étude tâche d’interpréter les différences des indices de résolution de gamma caméra obtenues expérimentalement et calculées. Les erreurs de mesurage et les conditions de validité des formules utilisées dans les calcules sont discutées. On a pu obtenir un agréement des deux méthodes et une confirmation théorique. On suggert de déterminer quelque condition de mesurage ou de remplacer les méthodes de mesurage par de calcul.

Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies

2006 ◽  
Vol 45 (03) ◽  
pp. 134-138 ◽  
Author(s):  
T. Kull ◽  
N. M. Blumstein ◽  
D. Bunjes ◽  
B. Neumaier ◽  
A. K. Buck ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Bone Marrow ◽  
Gamma Camera ◽  
Absorbed Dose ◽  
Correlation Coefficients ◽  
Residence Times ◽  
Reliable Prediction ◽  
Red Bone Marrow ◽  
Antibody Preparation ◽  
Simplified Method

SummaryAim: For the therapeutic application of radiopharmaceuticals the activity is determined on an individual basis. Here we investigated the accuracy for a simplified assessment of the residence times for a 188Re-labelled anti-CD66 monoclonal antibody. Patients, methods: For 49 patients with high risk leukaemia (24 men, 25 women, age: 44 ± 12 years) the residence times were determined for the injected 188Re-labelled anti-CD66 antibodies (1.3 ± 0.4 GBq, 5–7 GBq/mg protein, >95% 188Re bound to the antibody) based on 5 measurements (1.5, 3, 20, 26, and 44 h p.i.) using planar conjugate view gamma camera images (complete method). In a simplified method the residence times were calculated based on a single measurement 3 h p.i. Results: The residence times for kidneys, liver, red bone marrow, spleen and remainder of body for the complete method were 0.4 ± 0.2 h, 1.9 ± 0.8 h, 7.8 ± 2.1 h, 0.6 ± 0.3 h and 8.6 ± 2.1 h, respectively. For all organs a linear correlation exists between the residence times of the complete method and the simplified method with the slopes (correlation coefficients R > 0.89) of 0.89, 0.99, 1.23, 1.13 and 1.09 for kidneys, liver, red bone marrow, spleen and remainder of body, respectively. Conclusion: The proposed approach allows reliable prediction of biokinetics of 188Re-labelled anti-CD66 monoclonal antibody biodistribution with a single study. Efficient pretherapeutic estimation of organ absorbed dose may be possible, provided that a more stable anti-CD66 antibody preparation is available.

Sign in / Sign up

Export Citation Format

Share Document